Company Overview
About Talus Bio
Talus Bioscience is a Seattle-based AI-powered drug discovery company targeting transcription factors — the class of proteins historically considered "undruggable" that regulate gene expression and drive many cancers — using its proprietary MARMOT platform (MAssive Regulome Mapping Of Transcriptomes) to measure the binding activity of small molecules across 10,000+ regulomes monthly using live, unmodified human cells. Founded and backed by Y Combinator (W21) with $11.2 million in Seed+ funding raised in August 2024, Talus received FDA and EMA approval for Phase I human trials of its lead program MSD-001 in 2024 — advancing toward first-in-human studies for a transcription factor-targeted cancer therapy.
Business Model & Competitive Advantage
Talus' MARMOT platform addresses the fundamental challenge of targeting transcription factors: while transcription factors are implicated in 50%+ of human cancers, their protein surfaces lack the deep pockets that small molecule drugs typically bind to, making them resistant to conventional drug discovery approaches. MARMOT measures how potential drug molecules change the binding patterns of transcription factors across thousands of gene regulatory elements simultaneously — using native human cell systems rather than artificial model organisms — generating a functional readout of whether a molecule disrupts transcription factor activity in a biologically relevant context. This high-throughput functional screening approach identifies transcription factor-targeting compounds that would be missed by structure-based drug design.
Competitive Landscape 2025–2026
In 2025, Talus Bioscience competes in the targeted cancer therapy and AI drug discovery market with Black Diamond Therapeutics (NASDAQ: BDTX, cancer mutations), Blueprint Medicines (NASDAQ: BPMC, precision oncology), and AI drug discovery platforms (Recursion Pharmaceuticals, NASDAQ: RXRX) for transcription factor-targeted cancer program development. FDA and EMA Phase I approval for MSD-001 de-risks the most significant regulatory milestone for first-in-class transcription factor inhibitors and validates the MARMOT platform's output. Y Combinator's backing places Talus in the intersection of biotech and computational biology communities. The 2025 strategy focuses on advancing MSD-001 through Phase I safety trials, generating proof-of-concept data that enables partnership or out-licensing with larger pharmaceutical companies for Phase II/III development, and using MARMOT's platform capabilities for additional transcription factor targets.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Talus Bio is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Talus Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Talus Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Talus Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Talus Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →